Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery

• Status: Recruiting
• Trial end date: 2022-01-17
• Target enrollment: 0
• Participant gender: Female

Summary

Patients undergoing Partial or total mastectomy with axillary LN dissection will receive prior to induction of general anaesthesia ESP block at T4 level at the same side of the surgery. one group will receive ropivacaine 0.375% and the other will get ropivacaine 0.375% with dexmedetomidine 0.5mcg/kg as an adjuvant. time to first narcotic requirement will be documented and therefore an assessment of the duration of action of the block will be made

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lebanese American University
• Treatments: Dexmedetomidine; Ropivacaine

Criteria

Inclusion Criteria:

1. ASA class I, II and III patients

2. Age range: 18-80 years old

3. Elective partial or unilateral radical mastectomy with sentinel lymph node dissection

Exclusion Criteria:

1. Pregnant woman

2. Bilateral mastectomy.

3. Skin infection at the site of needle puncture

4. Coagulopathy problems

5. Allergy or contraindication to any of the study drugs

6. Recent use of opioid drugs